|
| Study | Model | Ischemic Protocol | Duration/onset of diabetes | Substrates | Model of diabetes | End points |
|
|
Hadour et al. (1998) [48] | Rabbit, 10% glucose infusion to 300 mg/dL blood glucose | In vivo nonrecovery, 30 min regional ischemia/3 hr reperfusion | Blood glucose maintained at 300 mg/dL throughout procedure | In vivo substrates | Type I diabetes | Infarction |
|
|
Tanaka et al. (2002) [62] | Dog, alloxan (40 mg/kg) and STZ (25 mg/kg) | In vivo nonrecovery, 60 min regional ischemia/3 hr reperfusion | 3 weeks | In vivo substrates | Type I diabetes | Infarction |
|
|
Ravingerová et al. (2003) [53] | Rat, STZ (45 mg/kg) | In vivo nonrecovery, 30 min regional ischemia/4 hr reperfusion | 8 weeks | In vivo substrates | Type I diabetes | Infarction |
|
|
Ebel et al. (2003) [31] | Rabbit- alloxan (100 mg/kg) | In vivo nonrecovery, 30 min regional ischemia/2 hr reperfusion | 6 weeks | In vivo substrates | Type I diabetes | Infarction |
|
|
Desrois et al. (2004) [63] | Aged Goto Kakisaki Rat, male | Langendorff isolated heart, 32 min low flow global ischemia/32 min reperfusion | In bred strain | 11 mmol/L glucose | Type II diabetes | Myocardial function |
|
|
Ma et al. (2006) [56] | Rat, STZ (50 mg/kg) | In vivo nonrecovery, 30 min regional ischemia/2 hr reperfusion | 6 weeks | In vivo substrates | Type I diabetes | Infarction |
|
|
Bulhak et al. (2009) [64] | Goto Kakizaki Rat, male | In vivo nonrecovery, 35 min regional ischemia/2 hr reperfusion | In bred strain | In vivo substrates | Type II diabetes | Infarction |
|
|
Matsumoto et al. (2009) [65] | Goto Kakizaki Rat, male | In vivo nonrecovery, 30 min regional ischemia/2 hr reperfusion | In bred strain | In vivo substrates | Type II diabetes | Infarction |
|
|
Shi-Ting et al. (2011) [58] | Rat, STZ (60 mg/kg) | Langendorff isolated heart, 30 min regional ischemia/40 min reperfusion | 8 weeks | 11 mmol/L glucose | Type I diabetes | Infarction and creatine kinase release |
|
